The T-Cell Transformation, ft. Dr. Philip Greenberg
The ImmunoVerse™
00:00
Scaling access and in vivo engineering
He predicts in vivo gene delivery to T cells will lower costs and enable wider, more efficient engineered T-cell therapies.
Play episode from 15:53
Transcript
